Tempest Total Assets vs Capital Stock Analysis

TPST Stock

USD 7.54 0.28 3.86%

Tempest Therapeutics financial indicator trend analysis is much more than just breaking down Tempest Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Tempest Therapeutics is a good investment. Please check the relationship between Tempest Therapeutics Total Assets and its Capital Stock accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tempest Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more information on how to buy Tempest Stock please use our How to Invest in Tempest Therapeutics guide.

Total Assets vs Capital Stock

Total Assets vs Capital Stock Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Tempest Therapeutics Total Assets account and Capital Stock. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Tempest Therapeutics' Total Assets and Capital Stock is -0.04. Overlapping area represents the amount of variation of Total Assets that can explain the historical movement of Capital Stock in the same time period over historical financial statements of Tempest Therapeutics, assuming nothing else is changed. The correlation between historical values of Tempest Therapeutics' Total Assets and Capital Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Assets of Tempest Therapeutics are associated (or correlated) with its Capital Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Stock has no effect on the direction of Total Assets i.e., Tempest Therapeutics' Total Assets and Capital Stock go up and down completely randomly.

Correlation Coefficient

-0.04

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Total Assets

Total assets refers to the total amount of Tempest Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Tempest Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Capital Stock

The total amount of a company's capital funded by shareholders through the issue and subscription of shares.

Most indicators from Tempest Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Tempest Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tempest Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more information on how to buy Tempest Stock please use our How to Invest in Tempest Therapeutics guide.At this time, Tempest Therapeutics' Selling General Administrative is comparatively stable compared to the past year. Enterprise Value is likely to gain to about 65.6 M in 2025, whereas Issuance Of Capital Stock is likely to drop slightly above 18.3 M in 2025.

Tempest Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Total Equity	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Property Plant And Equipment Net	Non Current Assets Total	Non Currrent Assets Other	Common Stock Shares Outstanding	Short Term Investments	Property Plant And Equipment Gross	Other Assets	Short Long Term Debt Total	Current Deferred Revenue	Net Receivables
Total Assets		0.75	0.69	0.87	-0.69	-0.68	0.68	0.68	0.91	0.54	-0.22	0.34	0.79	0.36	0.99	0.39	0.35	0.35	0.3	-0.03	0.53	0.34	-0.23	-0.02	-0.01	0.16
Other Current Liab	0.75		0.89	0.61	-0.61	-0.5	0.35	0.68	0.61	0.37	-0.15	0.48	0.52	0.62	0.76	0.17	0.14	0.15	0.25	-0.07	0.18	0.16	-0.2	0.19	0.0	0.69
Total Current Liabilities	0.69	0.89		0.52	-0.51	-0.69	0.45	0.7	0.53	0.45	-0.1	0.43	0.64	0.81	0.65	0.4	0.45	0.45	0.28	0.28	0.05	0.49	-0.23	0.47	-0.19	0.58
Total Stockholder Equity	0.87	0.61	0.52		-0.6	-0.5	0.61	0.51	0.84	0.36	-0.65	0.25	0.7	0.18	0.89	0.38	0.19	0.2	0.24	-0.1	0.6	0.2	-0.62	-0.16	0.07	0.07
Net Debt	-0.69	-0.61	-0.51	-0.6		0.56	-0.4	-0.9	-0.68	-0.21	0.15	-0.24	-0.31	-0.19	-0.74	-0.08	-0.02	0.07	-0.12	0.19	-0.09	-0.01	0.1	0.17	-0.17	-0.21
Retained Earnings	-0.68	-0.5	-0.69	-0.5	0.56		-0.58	-0.7	-0.64	-0.68	0.08	-0.02	-0.67	-0.51	-0.61	-0.72	-0.62	-0.54	-0.08	-0.44	-0.17	-0.62	0.18	-0.31	0.36	0.08
Accounts Payable	0.68	0.35	0.45	0.61	-0.4	-0.58		0.29	0.8	0.72	-0.22	-0.2	0.61	0.08	0.68	0.63	0.28	0.22	-0.14	0.06	0.68	0.27	-0.15	-0.22	-0.07	-0.14
Cash	0.68	0.68	0.7	0.51	-0.9	-0.7	0.29		0.56	0.22	-0.06	0.36	0.41	0.55	0.66	0.16	0.34	0.26	0.26	0.09	-0.15	0.34	-0.14	0.26	-0.05	0.32
Cash And Short Term Investments	0.91	0.61	0.53	0.84	-0.68	-0.64	0.8	0.56		0.71	-0.3	-0.05	0.68	0.15	0.93	0.46	0.22	0.16	-0.09	-0.18	0.73	0.2	-0.25	-0.24	0.12	0.06
Common Stock Total Equity	0.54	0.37	0.45	0.36	-0.21	-0.68	0.72	0.22	0.71		0.01	-0.41	0.54	0.26	0.52	0.72	0.37	0.29	-0.41	0.11	0.58	0.35	-0.01	0.04	-0.12	-0.03
Non Current Liabilities Total	-0.22	-0.15	-0.1	-0.65	0.15	0.08	-0.22	-0.06	-0.3	0.01		0.11	-0.19	0.08	-0.25	-0.32	0.11	0.12	0.08	0.02	-0.34	0.06	0.95	0.19	-0.01	0.01
Other Current Assets	0.34	0.48	0.43	0.25	-0.24	-0.02	-0.2	0.36	-0.05	-0.41	0.11		0.26	0.4	0.32	-0.32	0.11	0.28	0.93	0.06	-0.32	0.12	0.04	0.27	-0.04	0.34
Other Stockholder Equity	0.79	0.52	0.64	0.7	-0.31	-0.67	0.61	0.41	0.68	0.54	-0.19	0.26		0.49	0.74	0.54	0.63	0.64	0.32	0.27	0.47	0.64	-0.28	0.26	-0.16	0.03
Total Liab	0.36	0.62	0.81	0.18	-0.19	-0.51	0.08	0.55	0.15	0.26	0.08	0.4	0.49		0.29	0.18	0.71	0.7	0.29	0.33	-0.27	0.74	-0.18	0.87	-0.16	0.57
Total Current Assets	0.99	0.76	0.65	0.89	-0.74	-0.61	0.68	0.66	0.93	0.52	-0.25	0.32	0.74	0.29		0.31	0.24	0.24	0.25	-0.16	0.57	0.23	-0.22	-0.13	0.11	0.19
Common Stock	0.39	0.17	0.4	0.38	-0.08	-0.72	0.63	0.16	0.46	0.72	-0.32	-0.32	0.54	0.18	0.31		0.39	0.33	-0.17	0.66	0.35	0.42	-0.36	0.12	-0.64	-0.26
Property Plant And Equipment Net	0.35	0.14	0.45	0.19	-0.02	-0.62	0.28	0.34	0.22	0.37	0.11	0.11	0.63	0.71	0.24	0.39		0.96	0.26	0.47	-0.03	0.99	-0.13	0.76	-0.24	-0.1
Non Current Assets Total	0.35	0.15	0.45	0.2	0.07	-0.54	0.22	0.26	0.16	0.29	0.12	0.28	0.64	0.7	0.24	0.33	0.96		0.43	0.46	-0.03	0.96	-0.11	0.76	-0.22	-0.1
Non Currrent Assets Other	0.3	0.25	0.28	0.24	-0.12	-0.08	-0.14	0.26	-0.09	-0.41	0.08	0.93	0.32	0.29	0.25	-0.17	0.26	0.43		0.25	-0.3	0.26	0.0	0.28	-0.19	0.01
Common Stock Shares Outstanding	-0.03	-0.07	0.28	-0.1	0.19	-0.44	0.06	0.09	-0.18	0.11	0.02	0.06	0.27	0.33	-0.16	0.66	0.47	0.46	0.25		-0.34	0.52	-0.13	0.51	-0.88	-0.18
Short Term Investments	0.53	0.18	0.05	0.6	-0.09	-0.17	0.68	-0.15	0.73	0.58	-0.34	-0.32	0.47	-0.27	0.57	0.35	-0.03	-0.03	-0.3	-0.34		-0.06	-0.2	-0.51	0.25	-0.17
Property Plant And Equipment Gross	0.34	0.16	0.49	0.2	-0.01	-0.62	0.27	0.34	0.2	0.35	0.06	0.12	0.64	0.74	0.23	0.42	0.99	0.96	0.26	0.52	-0.06		-0.18	0.79	-0.26	-0.06
Other Assets	-0.23	-0.2	-0.23	-0.62	0.1	0.18	-0.15	-0.14	-0.25	-0.01	0.95	0.04	-0.28	-0.18	-0.22	-0.36	-0.13	-0.11	0.0	-0.13	-0.2	-0.18		-0.11	0.1	-0.07
Short Long Term Debt Total	-0.02	0.19	0.47	-0.16	0.17	-0.31	-0.22	0.26	-0.24	0.04	0.19	0.27	0.26	0.87	-0.13	0.12	0.76	0.76	0.28	0.51	-0.51	0.79	-0.11		-0.29	0.32
Current Deferred Revenue	-0.01	0.0	-0.19	0.07	-0.17	0.36	-0.07	-0.05	0.12	-0.12	-0.01	-0.04	-0.16	-0.16	0.11	-0.64	-0.24	-0.22	-0.19	-0.88	0.25	-0.26	0.1	-0.29		0.14
Net Receivables	0.16	0.69	0.58	0.07	-0.21	0.08	-0.14	0.32	0.06	-0.03	0.01	0.34	0.03	0.57	0.19	-0.26	-0.1	-0.1	0.01	-0.18	-0.17	-0.06	-0.07	0.32	0.14

Click cells to compare fundamentals

Tempest Therapeutics Account Relationship Matchups

Tempest Therapeutics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	22.9M	73.2M	46.1M	51.6M	41.5M	64.9M
Other Current Liab	1.4M	16.2M	3.3M	3.3M	3.5M	6.1M
Total Current Liabilities	3.2M	20.0M	7.3M	9.4M	14.2M	9.7M
Total Stockholder Equity	(68.8M)	36.1M	18.1M	26.8M	19.1M	30.3M
Net Debt	(16.4M)	(33.3M)	(9.1M)	(18.6M)	(14.9M)	(15.6M)
Retained Earnings	(71.8M)	(100.1M)	(135.8M)	(165.3M)	(207.1M)	(196.8M)
Accounts Payable	1.1M	991K	1.1M	845K	2.5M	1.3M
Cash	18.8M	51.8M	31.2M	39.2M	30.3M	35.8M
Cash And Short Term Investments	18.8M	51.8M	31.2M	39.2M	30.3M	43.5M
Liabilities And Stockholders Equity	22.9M	73.2M	46.1M	51.6M	41.5M	64.9M
Non Current Liabilities Total	88.4M	17.1M	20.7M	15.4M	8.1M	12.3M
Other Current Assets	745K	17.1M	1.4M	1.1M	1.2M	1.3M
Other Stockholder Equity	2.5M	136.2M	153.9M	192.0M	226.2M	139.6M
Total Liab	4.9M	37.1M	28.0M	24.8M	22.4M	15.2M
Total Current Assets	19.8M	69.0M	33.0M	40.4M	31.5M	43.3M
Common Stock	1K	7K	11K	22K	44K	46.2K
Property Plant And Equipment Net	3.0M	4.2M	12.7M	10.8M	9.5M	6.0M
Non Current Assets Total	3.0M	4.3M	13.1M	11.2M	10.0M	5.8M
Non Currrent Assets Other	51K	111K	429K	448K	485K	509.3K
Common Stock Shares Outstanding	31.2K	291.6K	888.4K	15.4M	27.9M	29.3M
Property Plant And Equipment Gross	2.2M	5.0M	12.7M	11.8M	10.8M	6.2M
Short Long Term Debt Total	2.4M	18.5M	22.1M	20.7M	15.4M	11.7M
Net Receivables	1.3M	260K	15M	450K	517.5K	491.6K
Short Term Debt	712K	1.4M	1.4M	5.2M	7.2M	7.6M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Tempest Stock Analysis

When running Tempest Therapeutics' price analysis, check to measure Tempest Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tempest Therapeutics is operating at the current time. Most of Tempest Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tempest Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tempest Therapeutics' price. Additionally, you may evaluate how the addition of Tempest Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC